Full text is available at the source.
Survodutide for the Treatment of Obesity
Survodutide as a Treatment for Obesity: Reasoning and Plan for the SYNCHRONIZE Heart Health Study
AI simplified
Abstract
A target recruitment of 4,935 participants is planned for the SYNCHRONIZE-CVOT study evaluating survodutide.
- Dual agonism of glucagon and GLP-1 receptors could be more effective in reducing body weight than GLP-1 receptor agonism alone.
- The cardiovascular effects of survodutide remain unknown.
- SYNCHRONIZE-CVOT is designed as a phase 3, randomized, double-blind, parallel-group study.
- The primary endpoint is the time to first occurrence of a composite of 5-point major adverse cardiovascular events.
- Participants include adults with a body mass index ≥27 kg/m² and established cardiovascular disease or chronic kidney disease.
AI simplified